Market Place
Sourcing Support
Omega Therapeutics To Present Multiple Posters At Scientific Meetings
15 Oct 2024 //
GLOBENEWSWIRE
Omega Publishes OTX-2002 Preclinical Data in Nature Comms
17 Sep 2024 //
GLOBENEWSWIRE
Omega Therapeutics Names Jennifer Nelson As Senior VP Of Research
14 Aug 2024 //
GLOBENEWSWIRE
Omega Therapeutics Reports Q2 2024 Results And Company Progress
06 Aug 2024 //
GLOBENEWSWIRE
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
24 Jun 2024 //
GLOBENEWSWIRE
Omega Therapeutics To Participate In Two Upcoming Investor Conferences
30 May 2024 //
GLOBENEWSWIRE
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
29 May 2024 //
GLOBENEWSWIRE
Novo Nordisk ties up with Metaphore to develop new obesity drugs
10 May 2024 //
REUTERS
Omega Gene Expression Preclinical Data At ASGCT 2024
08 May 2024 //
GLOBENEWSWIRE
Omega Reports Q1 2024 Results, Company Highlights
06 May 2024 //
GLOBENEWSWIRE
Omega Presents Epigenomic Data at ASGCT Annual Meeting
23 Apr 2024 //
GLOBENEWSWIRE
Omega Therapeutics Presents New Preclinical Data at AACR 2024
09 Apr 2024 //
GLOBENEWSWIRE
Omega cuts 35% of workforce; Rhythm, CervoMed, Surrozen raise new funding
01 Apr 2024 //
ENDPTS
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Omega Therapeutics Announces Two Poster Presentations
06 Mar 2024 //
GLOBENEWSWIRE
Novo Nordisk enters into research collaborations with Omega and Cellarity
04 Jan 2024 //
GLOBENEWSWIRE
Omega Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Omega to Participate in H.C. Wainwright 4th Annual Oncology Conference
04 Dec 2023 //
GLOBENEWSWIRE
Omega to Participate in the Piper Sandler 35th Annual Healthcare Conference
20 Nov 2023 //
GLOBENEWSWIRE
Omega Showcases Multiplexed Epigenomic Control of Gene Expression
13 Nov 2023 //
GLOBENEWSWIRE
Omega Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Omega Therapeutics to Participate in The Jefferies London Healthcare Conference
07 Nov 2023 //
GLOBENEWSWIRE
Omega Presents Data Demonstrating Pre-Transcriptional Modulation of CXCL Genes
31 Oct 2023 //
GLOBENEWSWIRE
Omega Presents New Preclinical Data Supporting the Potential of OTX-2101
16 Oct 2023 //
GLOBENEWSWIRE
Omega Therapeutics Announces Two Poster Presentations at AASLD
11 Oct 2023 //
GLOBENEWSWIRE
Omega Therapeutics to Present New Preclinical Data on OTX-2101
04 Oct 2023 //
GLOBENEWSWIRE
Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002
26 Sep 2023 //
GLOBENEWSWIRE
Omega Therapeutics` epigenomic medicines reduce MYC expression by 55%
26 Sep 2023 //
ENDPTS
Omega Therapeutics to Host Conference to Discuss Preliminary Data for OTX-2002
25 Sep 2023 //
GLOBENEWSWIRE
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
21 Sep 2023 //
GLOBENEWSWIRE
Omega Therapeutics Announces Updates to its Board of Directors
29 Aug 2023 //
GLOBENEWSWIRE
Omega Therapeutics Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Omega Therapeutics Appoints Chris Schade to its Board of Directors
12 Jul 2023 //
GLOBENEWSWIRE
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
Omega Presents Data Demonstrating the Potential of Omega Epigenomic Controllers
31 May 2023 //
GLOBENEWSWIRE
Omega Therapeutics Reports 1Q 2023 FYR and Highlights Recent Company Progress
04 May 2023 //
GLOBENEWSWIRE
Omega Therapeutics to Present New Preclinical Data at the ASCO 2023
27 Apr 2023 //
GLOBENEWSWIRE
Omega Announces Agreement to Evaluate the Combination of OTX-2002
30 Mar 2023 //
GLOBENEWSWIRE
Omega Therapeutics, Inc. (OMGA) Moves 15.2% Higher: Will This Strength Last?
17 Mar 2023 //
PRESS RELEASE
Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
01 Mar 2023 //
GLOBENEWSWIRE
Omega Announces $40 Million Registered Direct Offering of Common Stock
23 Feb 2023 //
GLOBENEWSWIRE
Omega to Present Trial-in-Progress Poster for Phase 1/2 MYCHELANGELO I Study
17 Jan 2023 //
GLOBENEWSWIRE
Omega Therapeutics Reports 3Q 2022 Financial Results and Recent Highlights
08 Nov 2022 //
PRNEWSWIRE
Omega Therapeutics to Participate in the Jefferies London Healthcare Conference
03 Nov 2022 //
PRNEWSWIRE
Omega Therapeutics Receives Orphan Drug Designation for OTX-2002
02 Nov 2022 //
PRNEWSWIRE
First patient receives new engineered mRNA epigenetic
28 Oct 2022 //
EUROPEANPHARMACEUTICALREVIEW
Omega Announces Patient Dosed in Landmark MYCHELANGELO I Trial of OTX-2002
27 Oct 2022 //
PRNEWSWIRE
Omega Unveils Epigenomic Controller Development Candidate Targeting Lung Cancer
12 Oct 2022 //
PRNEWSWIRE
FDA Approves Omega Therapeutics IND for First-Ever Epigenomic Controller Trial
18 Jul 2022 //
TRIALSITENEWS
Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002
14 Jul 2022 //
PRNEWSWIRE
Omega Tx to Present New PC Data for OTX-2002 for Hepatocellular Carcinoma
23 Jun 2022 //
PRNEWSWIRE
Omega Submits Investigational NDA for OTX-2002 for Hepatocellular Carcinoma
15 Jun 2022 //
PRNEWSWIRE
Omega Reports Q3 2021 Financial Results and Outlines Key Corporate Objectives
10 Nov 2021 //
PRNEWSWIRE
Omega taps Stanford to find targets for genome-tuning tech
14 Oct 2021 //
FIERCEBIOTECH
Omega Therapeutics Collaborates with Stanford University School of Medicine
14 Oct 2021 //
PRNEWSWIRE
Omega Reports Second Quarter 2021 Financial Results and Outlines Key Objectives
10 Sep 2021 //
PRNEWSWIRE
Omega Therapeutics Expands Board of Directors with Appointment of Luke Beshar
23 Jun 2021 //
PRNEWSWIRE
Omega Therapeutics to Advance Pipeline and Platform Development with $126 M
30 Mar 2021 //
PRNEWSWIRE
Omega grabs $126M to bring `genome-tuning` program into clinic
30 Mar 2021 //
FIERCEBIOTECH
Omega Therapeutics Announces the Industry`s First Programmable Epigenetic
13 Jan 2021 //
BIOSPACE
